B
Bull
Bull · 25%MOLN
$3.68
シナリオ価格
$4.210
-0.069 (-1.64%)終値時点
Loading chart…
- High
- 4.285
- Open
- 4.285
- VWAP
- 4.26
- Vol
- 968.00
- Mkt Cap
- 233.98M
- Low
- 4.285
- Amount
- 4.12K
- EV/EBITDA, TTM
- 0.00
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
AI analysis of Molecular Partners AG (MOLN)
buyMolecular Partners AG (MOLN) is a good buy right now due to its recent positive clinical trial advancements and a strong cash position of approximately $84 million, which is expected to fund operations into late 2027. The stock has shown a 20-day change of +8.17%, reflecting growing investor interest. However, the main risk is its negative earnings per share (EPS) of -0.44 reported in the last earnings, indicating ongoing financial challenges.
バリュエーション指標
The current forward P/E ratio for Molecular Partners AG (MOLN) is 1.70, compared to its 5-year average forward P/E of -1.13.
Alphio AI Price Scenarios for MOLN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MOLN
イベントタイムライン
ニュース
9.508-25NASDAQ.COMMolecular Partners Reports H1 2026 Financials and Pipeline Progress
9.508-25NewsfilterMolecular Partners Reports Clinical Progress and Financial Results for H1 2026
2.008-04GlobenewswireMolecular Partners Reports Progress on MP0533 Clinical Study
9.007-16NASDAQ.COMMolecular Partners Reports Clinical Progress in Cholangiocarcinoma Study
- 9.007-16Newsfilter
Molecular Partners Advances MP0317 Clinical Trial for Cholangiocarcinoma
MOLN FAQ — answered by Alphio AI
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. It operates in the Healthcare sector.
Molecular Partners AG (MOLN) is a good buy right now due to its recent positive clinical trial advancements and a strong cash position of approximately $84 million, which is expected to fund operations into late 2027. The stock has shown a 20-day change of +8.17%, reflecting growing investor interest. However, the main risk is its negative earnings per share (EPS) of -0.44 reported in the last earnings, indicating ongoing financial challenges.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。